As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Royalty Pharma Plc. The largest reported stake is Legorreta G. Pablo's, at 18.73%. 12 filings are on record since August 5, 2025 (Schedule 13D/A, August 17, 2026).
Sell to companies like Royalty Pharma Plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 14,091,863 · Shared voting: 0 · Sole dispositive: 19,288,880 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Legorreta G. Pablo · Sole voting: 7,934,830 · Shared voting: 93,851,013 · Sole dispositive: 7,934,830 · Shared dispositive: 84,508,014 · SCHEDULE 13D/A, 2026-08-17
- · Reporting person: Butterfield Fiduciary Administrators Trust Company Limited · Sole voting: 21,366,927 · Shared voting: 0 · Sole dispositive: 21,366,927 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-06-16
- · Reporting person: Capital International Investors · Sole voting: 37,448,042 · Shared voting: 0 · Sole dispositive: 37,772,419 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-14
- · Holder: Severgnini Achille G. · Percent: 5.7% · SCHEDULE 13D/A
Royalty Pharma Plc has 12 Schedule 13D or 13G filings on record since 2025-08-05. 3 holders' latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 18.73% | 101,785,843 | SCHEDULE 13D/A, 2026-08-17 | 2026-08-13 | |
| 9.2% | 38,907,011 | SCHEDULE 13G/A, 2025-08-05 | 2025-06-30 | |
| Capital International Investors | 8.8% | 37,772,419 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
| 4.8% | 21,366,927 | SCHEDULE 13D/A, 2026-06-16 | 2026-06-12 | |
| Fmr LLC | 4.3% | 19,288,880 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| General Atlantic, L.P. | 3.2% | 14,243,870 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| The Vanguard Group | 2.52% | 10,936,538 | SCHEDULE 13G/A, 2025-10-30 | 2025-09-30 |
Holding shares or following this stake? See who's behind Royalty Pharma Plc and the warning signs.
Free to see. No signup.
Keep reading
More on Royalty Pharma Plc and the records around it.
Royalty Pharma Plc elsewhere on the record
Companies that share a holder
- General Atlantic, L.P. also filed stake reports on 10 other companies: Korsana Biosciences, Inc. (Sep 2026), dLocal Ltd (Aug 2026), Pharvaris N.V. (Aug 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
- Morgan Stanley also filed stake reports on 182 other companies: MDA Space Ltd. (Nov 2026), RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (Oct 2026), Arbutus Biopharma Corp (Oct 2026)
Watch Royalty Pharma Plc
Get an email when Royalty Pharma Plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Royalty Pharma Plc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Royalty Pharma Plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Royalty Pharma Plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Legorreta G. Pablo | 7,934,830 | 93,851,013 | 7,934,830 | 84,508,014 | SCHEDULE 13D/A, 2026-08-17 |
| Legorreta Investments, LLC | 0 | 37,535,019 | 0 | 37,535,019 | SCHEDULE 13D/A, 2026-08-17 |
| Capital International Investors | 37,448,042 | 0 | 37,772,419 | 0 | SCHEDULE 13G/A, 2026-05-14 |
| Butterfield Fiduciary Administrators Trust Company Limited | 21,366,927 | 0 | 21,366,927 | 0 | SCHEDULE 13D/A, 2026-06-16 |
| Severgnini Achille G. | 21,366,927 | 0 | 21,366,927 | 0 | SCHEDULE 13D/A, 2026-06-16 |
| Fmr LLC | 14,091,863 | 0 | 19,288,880 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 19,288,880 | 0 | SCHEDULE 13G/A, 2026-11-05 |
The latest filing identifies Royalty Pharma Plc by CUSIP G7709Q104 and gives its principal executive office as 110 East 59th Street, New York, NY 10022 (SCHEDULE 13G/A, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Morgan Stanley | 9.2% | SCHEDULE 13G/A |
| 2025-08-13 | Capital International Investors | 5.5% | SCHEDULE 13G |
| 2025-08-14 | General Atlantic, L.P. | 3.2% | SCHEDULE 13G/A |
| 2025-10-30 | The Vanguard Group | 2.52% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 6.5% | SCHEDULE 13G/A |
| 2025-11-13 | Capital International Investors | 6.6% | SCHEDULE 13G/A |
| 2026-02-13 | Capital International Investors | 7.7% | SCHEDULE 13G/A |
| 2026-02-20 | Severgnini Achille G. | 5.7% | SCHEDULE 13D/A |
| 2026-05-14 | Capital International Investors | 8.8% | SCHEDULE 13G/A |
| 2026-06-16 | Severgnini Achille G. | 4.8% | SCHEDULE 13D/A |
| 2026-08-17 | Legorreta G. Pablo | 18.73% | SCHEDULE 13D/A |
| 2026-11-05 | Fmr LLC | 4.3% | SCHEDULE 13G/A |
Questions about who owns Royalty Pharma Plc
Who owns Royalty Pharma Plc?
On this page, 3 holders' latest ownership filings report 5% or more of Royalty Pharma Plc: Legorreta G. Pablo (18.73%, Schedule 13D/A, filed 2026-08-17), Morgan Stanley (9.2%, Schedule 13G/A, filed 2025-08-05) and Capital International Investors (8.8%, Schedule 13G/A, filed 2026-05-14).
Who are the largest shareholders of Royalty Pharma Plc?
By the share each holder's latest filing reports, the largest holders of Royalty Pharma Plc on this page are Legorreta G. Pablo (18.73%), Morgan Stanley (9.2%) and Capital International Investors (8.8%).
When did Legorreta G. Pablo buy into Royalty Pharma Plc?
The filings give report dates, not purchase dates. The earliest filing from Legorreta G. Pablo on this page is the Schedule 13D/A, filed 2026-08-17, reporting 18.73%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Royalty Pharma Plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.